Copyright © 2018 IPWatchdog, Inc.  Contact Us

The Unitary Patent:

The Unitary Patent and

the Unified Patent Court (UPC)

The Unitary Patent and the Unified Patent Court (UPC) were slated to come into effect at the end of 2017. For a variety of reasons, that deadline has come and gone without Europe ushering in a unified patent system. The new target for the beginning of the much-anticipated unified system is December 2018.

While there may be several good reasons to seek a Unitary patent, and to opt into the UPC, there are also a number of reasons why a Unitary Patent might not be the right choice, and important strategic reasons exist for opting out of the UPC – decisions that should not be left to the last minute. Furthermore, Germany has chosen to allow double patenting, which means even if you opt into the UPC, obtaining a separate German patent as a hedge seems extremely wise. 

In this webinar, we will discuss:

1.  What you need to know about the Unitary Patent and the Unitary Patent Court.

2.  Pros and Cons of the Unitary Patent.

3.  Pros and Cons of opting out of the Unitary Patent Court

4.  Obtaining a German patent as a hedge against uncertainty.

REGISTER FOR THE WEBINAR
REGISTER NOW

Is a Unitary Patent the right choice? Strategic reasons do exist for opting out of the UPC.


January 18th, 12:00 PM EST, 9:00 AM PST, 6:00 PM  CEST

About the Speakers

IPWatchdog.com Founder and Webinar Moderator

Gene is a patent attorney and a leading commentator on patent law and innovation policy. He is the Founder and Editor of IPWatchdog.com, which he started in 1999. IPWatchdog.com has been recognized multiple times by the American Bar Association as a top 100 legal blog.  Gene is regarded as an expert on software patentability and U.S. patent procedure.

Gene Quinn 

Tony Proctor

Partner, Potter Clarkson

Tony is a Patent Attorney and Litigator.  He is a specialist in matters relating to pharmaceutical inventions, including new chemical entities, pharmaceutical formulations and drug delivery technologies, new medical uses of known therapeutic agents, and medical diagnostic kits.  He also works with clients in the broader area of chemistry, with a particular interest in chemical processes and novel materials.  

• LIVE WEBINAR

Gene Quinn

IPWatchdog Founder  and Webinar Moderator

About Our Sponsor 

Morningside IP is a recognized leader in high-quality solutions for foreign patent filing, and one of the largest intellectual property translation companies in the world. Working with a global network of top-tier patent firms, we file patents in 175 countries and validate granted European patents in all EPO member states. We also provide patent translation services into more than 150 languages. With one set of instructions, Morningside IP can handle the entire patent filing process from start to finish — streamlining the process and significantly lowering filing and translation costs. Our clients include Fortune 500 patent departments, leading IP firms, and innovative companies around the world. With a global network of foreign agents, linguists and patent experts knowledgeable about country-specific requirements and the European patent system, Morningside IP is uniquely positioned to provide comprehensive services to meet all your patent translation and global filing needs.

REGISTER NOW

This Webinar Is Sponsored By

Strategy, Opportunities & Risks

Michael Fröhlich

EPO Director, European and International Legal Affairs

Michael is Director of European and International Legal Affairs, PCT at the European Patent Office (EPO). He is a fully qualified German lawyer with a Ph.D. and a post-graduate law degree in intellectual property. Michael has over 15 years of experience in the field of IP. His responsibilities at the EPO include the implementation of the Unitary Patent package, the procedural and substantive harmonisation of patent law, the further development of the European patent system, as well as the procedures and practice under the Patent Cooperation Treaty. 

Rob Bloom

Senior Associate, Morningside IP

Rob is a senior associate at Morningside IP, primarily responsible for advising Morningside's European clients regarding cost effective foreign filing options for both EP validations and PCT national phase. Since 2013, Rob has been successfully focusing his attention on helping significantly reduce the cost of clients' foreign patent filing, as well as streamlining their formalities processes in order to reduce the administrative burden of multinational filing. 

Fix the following errors:
Hide